COVID-19 has magnified the ramifications of India’s huge dependence on China for intermediates and active pharmaceutical ingredients. A new report delves into the areas where China holds advantages and what can be done to restore India’s competitiveness in API manufacturing, notwithstanding some recent government initiatives.
There’s been no dearth of warnings over the years by various stakeholders around India’s unhealthy dependence on China for critical intermediates and active pharmaceutical ingredients (APIs).
But the coronavirus pandemic has brought the issue front and center, exposing glaring supply chain gaps and the potential threat...
Mid-sized, diversified Japanese group teams up with Singaporean wholesaler Formiica and Japanese trading/contract services firm CBC for Singapore JV focused on in-licensing in Asia/Oceania.
Korean firm’s head of research talks to Scrip about how it is transforming into an innovative drug developer with a more diverse pipeline across multiple modalities with first-in-class potential.
The drugmaker announced topline results from the Phase III ATTAIN-2 trial in overweight/obese patients with type 2 diabetes and plans to file for approval.
